Ann: Appendix 4C - Quarterly, page-4

I reckon Jazz Pharma only one of the big players thinking the exact same thing the time saved paying EMD for access to there (RWE) data base could reap huge dividends$$$ for us shareholders.


As for the P3 trials, IMO I just cant see Jazz Pharma a ( US$10billmc ) company and the owner of the cash cow (Epidyolex) "the worlds only registered CBD medicine" sitting on the sidelines while EMD runs P3 trials going head to head against there baby, especially when you look at the below chart from the last trials.





If only EMD had a Jazz Pharma insider as a Director, a merger/acquisition or JV queen